Clariant and Huntsman to Merge


Another industry mega-merger has been announced, this time between Swiss specialty chemicals producer Clariant and US chemical company Huntsman. The multi-billion all-stock deal will see Clariant investors control 52% of the combined group, with Huntsman shareholders owning the remainder.
“This is the perfect deal at the right time. Clariant and Huntsman are joining forces to gain much broader global reach, create more sustained innovation power and achieve new growth opportunities,” said Clariant’s CEO, Hariolf Kottmann.
The new company will be called HuntsmanClariant and led by Peter Huntsman, CEO of Huntsman, while Kottmann will become chairman. The business will have a combined enterprise value of approximately $20 billion and will have dual listings on the Swiss and New York Stock Exchanges. Global headquarters will be in Pratteln, Switzerland, and operational headquarters will be in The Woodlands, Texas.
Both boards of directors have approved the merger, which they said will create a leading global specialty chemical company with sales of around $13.2 billion and an adjusted EBITDA of $2.3 billion. The combined company is expected to create more than $3.5 billion in value through annual cost synergies in excess of $400 million, which will be achieved by reducing operational costs and improving procurement.
The transaction is targeted to close by the end of 2017, subject to approvals from both companies’ shareholders, as well as regulatory clearances and other customary closing conditions.
Both companies have been the subject of merger rumors and speculation for many years and were reported to have held serious talks last autumn that apparently collapsed over which company would be the lead acquirer.
Huntsman has improved profitability in recent years by exiting certain businesses, such as surfactants, and closing production sites, for example pigment plants in France and South Africa. The US group is currently in the process of spinning off its titanium dioxide business into a separate firm named Venator and said plans will continue for the initial public offering (IPO) to take place as previously announced in the summer.
most read

Roche and Zealand Pharma Collaborate on Weight Management Drug
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Arkema Launches Acrylic Acid Purification Project
Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Ineos Invests £30 Million to Slash Emissions at Hull Site by 75%
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.

BASF Divests Two Joint Ventures in China
BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Oxea Appoints Michael McHenry as New Chief Executive Officer
German oxo-chemicals manufacturer Oxea has appointed Michael McHenry as its new CEO with effect from August 15, 2025.